anxiety/vomiting

The present invention relates to a method of treatment of emesis, such as cytotoxic agent or radiation induced nausea and vomiting or motion sickness; anxiety; and irritable bowel syndrome (IBS); in mammals including humans, and to the use of compounds in the preparation of a medicament for the

The present invention relates to a method of treatment of emesis, such as cytotoxic agent or radiation induced nausea and vomiting or motion sickness; anxiety; and irritable bowel syndrome (IBS); in mammals including humans, and to the use of compounds in the preparation of a medicament for the

BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs

This invention relates to a class of spirocyclic compounds which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal or dependence; pain; gastric stasis; gastric dysfunction (such as occurs with dyspepsia, peptic ulcer, reflux

This invention relates to a class of 5-membered heterocyclic compounds having at least one heteroatom, which are useful in the treatment of psychotic disorders (e.g. schizophrenia and mania); anxiety; alcohol or drug withdrawal; pain; gastric stasis; gastric dysfunction (such as occurs with

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a series of substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones. More specifically, the present invention relates to a series of substituted

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a series of substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones. More specifically, the present invention relates to a series of 2-substituted-di- tri or

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones. More specifically, the present invention relates to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and

CROSS REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. .sctn.119 from GB Application No. 0108971.3, filed Apr. 10, 2001. The present invention provides compounds of the formula (I): ##STR2## wherein X represents hydrogen or a C.sub.1-4 alkyl group optionally

This invention relates to a class of tetrahydropyran compounds which are useful as tachykinin antagonists. More particularly, the compounds of the invention are useful as neurokinin 1 (NK-1) receptor antagonists. By virtue of their excellent specificity for the human NK-1 receptor, the compounds of

BACKGROUND OF THE INVENTION Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. The tachykinins are distinguished by a conserved

This invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which are potent and selective antagonists of 5-hydroxytryptamine (5-HT) at 5-HT receptors of

This invention relates to heterocyclic compounds, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to compounds which act upon 5-hydroxytryptamine (5-HT) receptors of the type located on terminals of

BACKGROUND OF THE INVENTION Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. The tachykinins are distinguished by a conserved